Planned
There are currently no planned studies in our center.
Ongoing
There are currently no ongoing studies in our center.
Closed
CHECKMATE 498 CA209-498
A randomized phase III open-label study of nivolumab vs temozolomide each in combination with radiation therapy in newly diagnosed adult subjects with unmethylated MGMT glioblastoma
- Principal investigator : Prof. Dr. Paul Clement
- Sponsor : Bristol-Myers Squibb
- More information : NCT02617589
- Indication :
- Internal reference number : s58944
CHECKMATE 548 CA209-548
A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination With Radiation Therapy in Newly Diagnosed Adult Subjects With Unmethylated MGMT (Tumor O-6-methylguanine DNA Methyltransferase) Glioblastoma
- Principal investigator : Prof. Dr. Paul Clement
- Sponsor : Bristol-Myers Squibb
- More information : NCT02667587
- Indication :
- Internal reference number : s58986
INTELLANCE 1 M13-813
A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification
- Principal investigator : Prof. Dr. Paul Clement
- Sponsor : AbbVie
- More information : NCT02573324
- Indication :
- Internal reference number : s58522
STELLAR OT-15-001
A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy
- STELLAR : Prof. Dr. Paul Clement
- Sponsor : Orbus
- More information : NCT02796261
- Indication :
- Internal reference number : s60188